Annexon, Inc. Files 8-K Report
Ticker: ANNX · Form: 8-K · Filed: May 7, 2024 · CIK: 1528115
Sentiment: neutral
Topics: sec-filing, corporate-update
TL;DR
Annexon filed a standard 8-K, no major news.
AI Summary
On May 7, 2024, Annexon, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific new material events or financial figures detailed in the provided excerpt. The report confirms Annexon's identity and basic corporate information.
Why It Matters
This filing serves as a routine update and confirmation of Annexon's corporate information with the SEC, indicating ongoing compliance and reporting.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information that suggests a change in risk for the company.
Key Players & Entities
- Annexon, Inc. (company) — Registrant
- May 7, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1400 Sierra Point Parkway, Bldg C, Suite 200 Brisbane, California 94005 (address) — Principal executive offices
- (650) 822-5500 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Annexon, Inc.?
The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits," serving as a current report to the SEC.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on May 7, 2024.
In which state is Annexon, Inc. incorporated?
Annexon, Inc. is incorporated in Delaware.
What is Annexon, Inc.'s principal executive office address?
Annexon, Inc.'s principal executive office is located at 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005.
What is the SIC code for Annexon, Inc.?
The Standard Industrial Classification (SIC) code for Annexon, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 477 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-05-07 16:05:07
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ANNX The Nasdaq Stock Mar
Filing Documents
- d825274d8k.htm (8-K) — 24KB
- d825274dex991.htm (EX-99.1) — 26KB
- g825274gra001a.jpg (GRAPHIC) — 3KB
- 0001193125-24-133086.txt ( ) — 184KB
- annx-20240507.xsd (EX-101.SCH) — 3KB
- annx-20240507_lab.xml (EX-101.LAB) — 18KB
- annx-20240507_pre.xml (EX-101.PRE) — 11KB
- d825274d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated May 7, 2024, titled "Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting." 104.1 Cover Page Interactive Data File, formatted in inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 7, 2024 Annexon, Inc. By: /s/ Jennifer Lew Jennifer Lew Executive Vice President and Chief Financial Officer